ERBB2 and neoplasm: Among the HER2-amplified tumours, 43.3% (n=13) showed moderate HER2 amplification (HER2/GAPDH ratio 2.0–4.0) and 56.7% (n=17) a strong amplification (HER2/GAPDH ratio⩾4.0).